15 February 2017 - Case of the Week #417

All cases are archived on our website. To view them sorted by case number, diagnosis or category, visit our main Case of the Week page. To subscribe or unsubscribe to Case of the Week or our other email lists, click here.

Thanks to Dr. Sandhya Sundaram, Professor & Senior Consultant, Sri Ramachandra Medical College & Research Institute, Chennai (India) for contributing this case and Dr. Belinda Lategan, St. Boniface Hospital (Canada) for writing the discussion. To contribute a Case of the Week, follow the guidelines on our main Case of the Week page.




Please visit us at USCAP and meet Dr. Pernick.
We will be located in Booth #413.
We will look forward to seeing you in March!
 


Advertisement


Website news:

(1) We have a number of new management articles that have been posted on our Management page. Some of the articles written by Vachette's Mick Raich are, "Examining The Differences Between PQRS And MIPS", "Want To Avoid Medicare Penalties Under MACRA?" and "Commercial Insurers Aim To Lower Lab Reimbursements With Pre-Authorization Programs".

(2) Roche is offering a webinar on Lab Leaders on March 1 and ARUP is offering new CME courses. You can also see new Education product information posted by Educational Symposia and Oakstone. Also, read about Bio SB's new product on our New Products and Services Page.

(3) We have been getting a flood of "bounces" for our subscription emails to Rediffmail accounts. If you have one of these accounts and want to continue to receive our emails for Case of the Week, What's New, Jobs, Monthly Website News or our Commercial Email, please provide us an alternative email address via the Newsletters link.

Visit and follow our Blog to see recent updates to the website.



Case of the Week #417

Clinical history:
A 60 year old woman presented with rectal bleeding. Examination revealed a rectal mass. CT scan showed a soft tissue mass in the left hypochondrium which encircled the rectum. Multiple omental deposits were also seen.

The rectal mass and an omental nodule were biopsied.


Radiology images:

CT Soft tissue mass in the left hypochondrium

Lesion seen encircling colon and rectum



Micro images:

Rectal tissue and a separate tumor fragment with papillary pattern x100

Papillary arrangement of tumor x200

Lining cells are pleomorphic and hyperchromatic x400


































Diagnosis:
Primary peritoneal serous carcinoma (PPSC)


Special Stains:

CK7 - strongly positive in tumor, negative in rectal mucosa

WTI - nuclear positivity in tumor and negative in rectal mucosa

CK20 - positivity in normal rectal mucosa, negative in tumor cells

CDX2 - nuclear positivity in normal rectal mucosa, negative in tumor cells



Test question (answer at the end):
Immunohistochemistry can reliably distinguish between serous carcinomas of ovarian, fallopian tube and peritoneal origin.

A. True
B. False

Discussion:

Histopathology from the rectal mass and omental nodule showed a malignant neoplasm arranged in a papillary pattern, lined by pleomorphic hyperchromatic cells. Occasional mitotic figures were seen.

Primary peritoneal serous carcinoma (PPSC) morphologically resembles serous carcinoma of the ovary and fallopian tube, and may similarly be divided into low grade and high grade subtypes. The diagnosis requires that both ovaries and fallopian tubes are grossly and microscopically normal or only minimally involved (surface involvement only). If involvement of the ovary or fallopian tube is present, the extra-ovarian disease must be more extensive. The fallopian tubes can only be excluded as a site of origin after careful examination using the SEE-Fim-protocol (Mod Pathol 2014;27:1002) has excluded a serous tubal intraepithelial carcinoma (STIC) or small focus of high grade serous carcinoma (HGSC). However, the distinction is not critical, as behavior and management are determined by grade and clinical stage, regardless of the site of origin (Mod Pathol 2015;28:1101)

Differential diagnosis and ancillary studies:
The differential diagnosis includes ovarian or fallopian tube serous tumors, mesothelial proliferations or peritoneal involvement by non-serous/non-mullerian malignancy. Careful review of the clinical history, imaging, operative findings and ancillary studies is necessary to confirm the diagnosis.

Immunohistochemistry is not helpful in distinguishing PPSC from its counterparts in the ovary and fallopian tube, as the profiles are near identical. Malignant mesothelioma can be excluded by utilizing a panel of immunohistochemical studies. Both entities will usually express WT1, and the addition of Calretinin, PAX8, CK5/6 and ER may be helpful in the differentiation.

WT1PAX8CalretininCK5/6ER
Mesothelial proliferations+-/focal +++++++-
PPSC++++--/focal ++++


Other IHC markers can be included in the panel if non-mullerial malignancies are also being considered.

Molecular analysis of PPSC demonstrated an association with germline mutations of the BRCA1 gene and necessitates follow up for PPSC in addition to breast and ovarian carcinomas in BRCA1 carriers.

In this case, the differential diagnosis also included colon carcinoma. Immunohistochemistry was performed for CK7, CK20, WT1 and CDX2. CK7 and WT1 were strongly positive and CK20 and CDX2 were negative in the omental nodule and rectal mass, which ruled out a primary colorectal tumor. Imaging studies were reassessed for evidence of an ovarian origin; both ovaries were normal. A diagnosis of primary peritoneal serous carcinoma was rendered.

Primary peritoneal serous carcinoma presenting as a dominant rectal mass with clinical symptoms mimicking a primary rectal carcinoma is exceedingly rare. IHC proved useful for this diagnosis.

Test Question Answer:
B. False

Immunohistochemistry is not helpful in distinguishing PPSC from serous carcinoma arising in the ovary and fallopian tube, as the profiles are near identical. Careful review of the clinical history, imaging and operative findings is necessary to confirm the diagnosis. However, the distinction may not be critical as behavior and management is determined by grade and clinical stage, regardless of the site of origin.

Additional references:

J Clin Oncol 2015;33:2675, WHO classification of Tumours of the Female Reproductive Organs (4th ed. 2014), Gynecol Oncol Res Pract 2015;2:1